Anales de la RANM

255 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TRASPLANTE DE ÓRGANOS Y REMODELADO ÓSEO Federico Hawkins Carranza An RANM · Año 2019 · número 136 (03) · páginas 249 a 255 23. Shane E, Rivas M, McMahon DJ, Staron RB, Sil- verberg SJ, Seibel MJ. Bone loss and turnover af- ter cardiac transplantation. J Clin Endocrinol Metab 1997; 82(5): 1497-1506. 24. Pisani B, Mullen GM. Prevention of osteoporosis in cardiac transplant recipients. Curr Opin Car- diol 2002; 17(2): 160-164. 25. Maalouf NM, Shane E. Osteoporosis after solid or- gan transplantation. J Clin Endocrinol Metab 2005; 90(4): 2456-2465. 26. Chauhan V, Ranganna KM, Chauhan N, Vaid M, Kelepouris E. Bone disease in organ transplant pa- tients: pathogenesis and management. Postgrad Med 2012; 124(3): 80-90. 27. Kulak CA, Borba VZ, Kulak Júnior J, Shane E. Transplantation osteoporosis. Arq Bras Endocrinol Metabol 2006; 50(4): 783-792. 28. Stein E, Ebeling P, Shane E. Post-transplanta- tion osteoporosis. Endocrinol Metab Clin North Am 2007; 36(4): 937-963. 29. Sun L, Blair HC, Peng Y , et al. Calcineurin regu- lates bone formation by the osteoblast Proc Natl Acad Sci U S A 2005; 102(47): 17130-17135. 30. Sun L, Peng Y, Zaidi N, et al. Evidence that calci- neurin is required for the genesis of bone-resor- bing osteoclasts.A m J Physiol Renal Physiol 2007; 292(1): F285-291. 31. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral me- tabolism in vivo. Transplantation 1994 27; 57(8): 1231-1237. 32. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skele- ton. J Bone Miner Res 1996; 11(1): 1-7. 33. Bowman AR, Sass DA, et al. The role of testoste- rone in cyclosporine-induced osteopenia. J Bone Miner Res 1997; 12(4): 607-615. 34. Martínez Díaz-Guerra G, Gómez R, Jódar E, Loinaz C, Moreno E, Hawkins F. Long-term fo- llow-up of bone mass after orthotopic liver trans- plantation: Effect of steroid withdrawal from the immunosuppressive regimen. Osteoporos Int 2002; 13(2): 147-150. 35. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immu- nosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997 15; 63(3): 380-386. 36. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP . Osteoporosis after cardiac trans- plantation. Am J Med 1993; 94(3): 257-264. 37. Anijar JR, Szejnfeld VL, Almeida DR, Fernandes AR, Ferraz MB. Reduced bone mineral density in men after heart transplantation. Braz J Med Biol Res 1999; 32(4): 413-420. 38. Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppres- sion on bone mineral density and bone turnover after cardiac transplantation: a prospective, lon- gitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002 27; 73(4): 547- 552. 39. Goffin E, Devogelaer JP, Lalaoui A, et al. Tacro- limus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002; 15(2-3): 73-80. 40. Bryer HP, Isserow JA, Armstrong EC, et al. Aza- thioprine alone is bone sparing and does not al- ter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10(1): 132-138. 41. Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid- induced osteoporosis. Biochem Biophys Res Com- mun 2009 6; 379(2): 261-266. 42. Giannini S, Nobile M, Ciuffreda M, et al. Long- term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 2000; 11(5): 417-424. 43. Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. Osteoporosis after organ transplanta- tion. Lancet 2001 19; 357(9268): 1623. 44. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl 2004; 10(5): 638-647. 45. Gilfraguas L, Guadalix S, Martínez G, et al. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin and calcium plusvitamin D3. Prog Transplant 2012; 22(3): 237-243. 46. Nel JD, Epstein S. Metabolica bone disease in the post-transplant population. Med Clin Nam 2016; 100: 569-586. 47. Guadalix S, Martínez-Díaz Guerra G, Lora D, et al. Effect of early risedronate treatment onbone min- eral density and bone turnover markers after liver transplantation: a prospective single-center study. Transplant Int 2011; 24 (7): 657-665. 48. Librizzi MS, Guadalix S, Martínez-Díaz Guerra G, et al. Trabecular bone score in patients with liver transplants after1 year of risedronate treatment. Transpl Int 2016; 29(3): 331-337. DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en la presente revisión. Si desea citar nuestro artículo: Hawkins-Carranza F. Trasplante de órganos y remodeIado óseo ANALES RANM [Internet]. Real Academia Nacional de Medicina de España; An RANM · Año 2019 · número 136 (03) · páginas 249 – 255 DOI: 10.32440/ar.2019.136.03. rev03